Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

View Funded Institutions
View Funded Investigators
Find Clinical Trials

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Parkinson’s Institute R. Jeremy Nichols Basic Biology III Understanding the role of LRRK2 in iPSC cell models of Parkinson’s Disease $1,482,822
Scripps Research Institute Kristin Baldwin Basic Biology III Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing $1,705,500
University of California, Berkeley Dr. Michael P. Rapé Dr. Basic Biology III Ubiquitin-dependent control of hESC self-renewal and expansion $1,224,805
University of California, Los Angeles UCLA Gay Miriam Crooks Basic Biology III Forming the Hematopoietic Niche from Human Pluripotent Stem Cells $1,252,857
University of California, San Diego Dr. Charles C. King Dr. Basic Biology III Biological relevance of microRNAs in hESC differentiation to endocrine pancreas $1,313,649
University of California, Berkeley Dr. Song Li Basic Biology III Induced Pluripotent Stem Cells for Tissue Regeneration $1,209,148
University of California, San Diego Karl H. Willert Tools and Technologies II Homologous recombination in human pluripotent stem cells using adeno-associated virus. $1,659,043
Stanford University Dr. Marius Wernig MD, PhD Tools and Technologies II Cellular tools to study brain diseases affecting synaptic transmission $1,664,382
Stanford University Professor Irving L Weissman MD Tools and Technologies II Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs $1,463,814
TriFoil Imaging, Inc. Dr. Joann Zhang Tools and Technologies II Tri-resolution Visualization System for Stem Cells and Tissue Regeneration Monitoring $1,456,989
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Tools and Technologies II Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. $1,933,022
University of California, Berkeley John Dueber Tools and Technologies II Engineering Defined and Scaleable Systems for Dopaminergic Neuron Differentiation of hPSCs $1,340,816
Stanford University Dr. Brian K. Rutt Tools and Technologies II Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters $1,833,348
Parkinson’s Institute Dr. Birgitt Schuele Tools and Technologies II Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases $1,327,983
University of California, San Francisco Dr. Daniel A. Lim MD, PHD Tools and Technologies II Development and preclinical testing of new devices for cell transplantation to the brain. $1,795,891
GMR Epigenetics Dr. Jifan Hu Tools and Technologies II Robust generation of induced pluripotent stem cells by a potent set of engineered factors $1,356,052
Stanford University Sarah Heilshorn Tools and Technologies II Preparation and Delivery of Clinically Relevant Numbers of Stem Cells Using 3D Hydrogels $600,695
University of California, San Diego Dr. Lawrence S. B. Goldstein Tools and Technologies II Developing a method for rapid identification of high-quality disease specific hIPSC lines $1,686,069
University of California, Los Angeles Dr. Richard A. Gatti Tools and Technologies II Use of hiPSCs to develop lead compounds for the treatment of genetic diseases $1,833,054
Stanford University Dr. Theo D. Palmer PhD Tools and Technologies II Development of small molecule screens for autism using patient-derived iPS cells $1,797,606
University of California, Berkeley Dr. Steven M. Conolly Tools and Technologies II Magnetic Particle Imaging: A Novel Ultra-sensitive Imaging Scanner for Tracking Stem Cells In Vivo $1,311,596
University of California, San Diego Shu Chien Tools and Technologies II Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation $1,706,628
University of California, Los Angeles Dr. Thomas Carmichael M.D., Ph.D. Tools and Technologies II Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke $1,825,613
Stanford University Dr. Michele Calos Tools and Technologies II Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation $1,592,897
Fluidigm Corporation Dr. Marc A Unger Tools and Technologies II Development and Application of Versatile, Automated, Microfluidic Cell Culture System $1,939,236
University of California, Los Angeles Dr. Martin Gabriel Martin Tools and Technologies II Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders $1,783,250
Stanford University Dr. Katja Weinacht Preclinical Stage Projects Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells $12,999,871
EVADE Therapeutics Sonja Schrepfer Preclinical Stage Projects Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes $12,480,000
University of Southern California Charles Murry Preclinical Stage Projects Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. $7,499,998
University of California, Los Angeles Dr. Lili Yang Preclinical Stage Projects Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis $7,499,996
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events $12,714,480
4D Molecular Therapeutics, Inc. Sara Collins Preclinical Stage Projects Gene Therapy for Alpha-1 Anti-Trypsin Deficiency $5,915,073
AcuraStem Incorporated Mr. Samuel V. Alworth MS, MBA Preclinical Stage Projects Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies $7,500,000
Cure Rare Disease Dr. Tahseen Mozaffar Preclinical Stage Projects Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 $7,292,297
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia $13,000,000
Savanna Biotherapeutics, Inc. Dr. Sunil Gandhi Ph.D Preclinical Stage Projects Microglia replacement therapy for CSF1R-related Leukoencephalopathy $12,993,456
Cedars-Sinai Medical Center Dr. David Joseph Lefer Preclinical Stage Projects TY1 and Semaglutide to Treat Cardiometabolic HFpEF $10,571,220
University of California, San Diego Dr. Stephanie Cherqui Preclinical Stage Projects CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia $7,423,504
Cedars-Sinai Medical Center Dr. Alessandra Ciullo Preclinical Stage Projects Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy $10,419,929
Navega Therapeutics Ana Maria Moreno Preclinical Stage Projects Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders $9,486,864
Scripps Health Dr. Darryl D. D’Lima Preclinical Stage Projects Stem Cell-Based Cartilage Tissue Regeneration $12,715,000
Stanford University Dr. Bertha Chen Preclinical Stage Projects Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence $7,275,596
Loma Linda University Hisham Abdel-Azim CCCE Grant Inland Empire and Desert Region CIRM Community Care Center of Excellence $9,000,000
Fresno Community Hospital and Medical Center Haifaa Abdulhaq CCCE Grant Establishing a CIRM Community Care Center of Excellence in the Central Valley $8,996,101
Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center Lynda Polgreen MD CCCE Grant South Los Angeles Community Center of Excellence for Regenerative Medicine $9,000,000
Stanford University Dr. Michael P Snyder PhD ReMIND – Discovery Stage ReMIND Dissecting cell-specific genetic and molecular drivers of amyotrophic lateral sclerosis for therapeutic insights $12,999,837
Stanford University Sergiu P Pasca ReMIND – Discovery Stage ReMIND Transplantation of human forebrain assembloids as a platform for therapeutic screening in neurodevelopmental disorders $13,999,999
University of California, Los Angeles Daniel Geschwind ReMIND – Discovery Stage ReMIND Advancing Therapeutic Discovery Through Multimodal Analyses of Genetic and Cellular Mechanisms in Neuropsychiatric Disorders $13,957,175
University of California, San Diego Dr. Gene Wei-Ming Yeo ReMIND – Discovery Stage ReMIND Reversing age-dependent neurodegeneration by elimination of RNA pollution $11,946,234
Salk Institute for Biological Studies Christian Metallo ReMIND – Discovery Stage ReMIND Tracing the metabolic basis of neurological disorders $12,995,613
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 … 32